BCRX ▼ -0.4% - BioCryst Pharmaceuticals, Inc.
$BCRX - BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
13-NOV-2026 07:00 AM ET
Share this post
More filings for $BCRX
BCRX ▼ -4.1% - BioCryst Pharmaceuticals, Inc.Nov 4, 2026BCRX ▲ +1.6% - BioCryst Pharmaceuticals, Inc.Nov 4, 2026BCRX ▲ +3.4% - BioCryst Pharmaceuticals, Inc.Nov 4, 2026BCRX ▲ +0.1% - BioCryst Pharmaceuticals, Inc.Oct 29, 2026BCRX ▼ -2.6% - BioCryst Pharmaceuticals, Inc.Oct 21, 2026BCRX ▲ +1.0% - BioCryst Pharmaceuticals, Inc.Oct 21, 2026
View full $BCRX filing history →💬 Comments
Loading comments…
Leave a comment